• Explore /
  • Poster
  • / Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

Abstract Poster

Authors

Andrea Apolo

Andrea B. Apolo

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Andrea B. Apolo , Jeffrey R. Infante , Omid Hamid , Manish R. Patel , Ding Wang , Karen Kelly , Anthony E. Mega , Carolyn D. Britten , Alain Ravaud , Alain C. Mita , Howard Safran , Tom Stinchcombe , Hans Juergen Grote , Anja von Heydebreck , Jean-Marie Cuillerot , James L. Gulley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT01772004

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4514)

DOI

10.1200/JCO.2016.34.15_suppl.4514

Abstract #

4514

Poster Bd #

137

Abstract Disclosures

Similar Posters

First Author: Manish R. Patel

First Author: Mary L. Disis

First Author: Andrea B. Apolo

First Author: Claire F. Verschraegen